About Hexokinase-4
Hexokinase-4 (GCK) is a protein
from Homo sapiens identified by UniProt accession
P35557, 465 residues long.
MolForge cross-references it against 0 known binders and
339 disease associations.
Target properties
| Protein name | Hexokinase-4 |
| UniProt accession | P35557 |
| Gene | GCK |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (339)
Diseases linked to this target (Open Targets).
- MODY · score 0.85
- type 2 diabetes mellitus · score 0.85
- maturity-onset diabetes of the young type 2 · score 0.84
- permanent neonatal diabetes mellitus 1 · score 0.80
- hyperinsulinism due to glucokinase deficiency · score 0.78
- diabetes mellitus · score 0.75
- maturity-onset diabetes of the young · score 0.70
- HbA1c measurement · score 0.70
- glucose measurement · score 0.69
- monogenic diabetes · score 0.68
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35557-F1 | alphafold | PREDICTED | 93.69 | — |
Amino-acid sequence (465 residues)
MLDDRARMEA AKKEKVEQIL AEFQLQEEDL KKVMRRMQKE MDRGLRLETH EEASVKMLPT YVRSTPEGSE VGDFLSLDLG GTNFRVMLVK VGEGEEGQWS VKTKHQMYSI PEDAMTGTAE MLFDYISECI SDFLDKHQMK HKKLPLGFTF SFPVRHEDID KGILLNWTKG FKASGAEGNN VVGLLRDAIK RRGDFEMDVV AMVNDTVATM ISCYYEDHQC EVGMIVGTGC NACYMEEMQN VELVEGDEGR MCVNTEWGAF GDSGELDEFL LEYDRLVDES SANPGQQLYE KLIGGKYMGE LVRLVLLRLV DENLLFHGEA SEQLRTRGAF ETRFVSQVES DTGDRKQIYN ILSTLGLRPS TTDCDIVRRA CESVSTRAAH MCSAGLAGVI NRMRESRSED VMRITVGVDG SVYKLHPSFK ERFHASVRRL TPSCEITFIE SEEGSGRGAA LVSAVACKKA CMLGQ
Explore Hexokinase-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets